Aclaris Therapeutics Inc. (NASDAQ:ACRS) is one of the most promising penny stocks under $5. On July 29, Aclaris Therapeutics announced positive top-line results from its Phase 2a clinical trial of ATI-2138. This is a potent and selective oral inhibitor of interleukin-2-inducible T cell kinase/ITK and Janus kinase 3/JAK3, which are both enzymes involved in immune responses.
The trial was an open-label, single-arm study conducted with 14 patients who had moderate-to-severe atopic dermatitis/AD. The company intends to further develop ATI-2138 for alopecia areata and other immuno-inflammatory diseases. The trial successfully achieved its primary and key secondary endpoints.
A scientist conducting a clinical trial on a patient to test the efficacy of a new drug.
The primary endpoint, which focused on safety, confirmed that ATI-2138 has a favorable tolerability profile without the significant safety risks often associated with other JAK inhibitors. No severe adverse events/SAEs or treatment-emergent adverse events/TEAEs were observed. The efficacy results showed clinically meaningful improvements in disease severity.
Aclaris Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops novel drug candidates for immune-inflammatory diseases in the US.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
